Intracerebral Hemorrhage Deferoxamine Trial - iDEF Ttrial

Summary

The investigators hypothesize that treatment with the iron chelator, Deferoxamine Mesylate, improves the outcome of patients with brain hemorrhage.

The purpose of this study is to determine whether treatment with Deferoxamine Mesylate is of sufficient promise to improve outcome before pursuing a larger clinical trial to examine its effectiveness as a treatment for intracerebral hemorrhage.

Conditions

• Intracerebral Hemorrhage

Interventions

DRUG

Deferoxamine Mesylate

DRUG

Placebo (for Deferoxamine Mesylate)

Sponsors & Collaborators

• Medical University of South Carolina

  collaborator OTHER

• National Institute of Neurological Disorders and Stroke (NINDS)

  collaborator NIH

• Massachusetts General Hospital

  collaborator OTHER

• University of Massachusetts, Worcester

  collaborator OTHER

• University of Pennsylvania

  collaborator OTHER

• Johns Hopkins University

  collaborator OTHER

• Duke University

  collaborator OTHER

• University of North Carolina

  collaborator OTHER

• University of Florida

  collaborator OTHER

• Henry Ford Hospital

  collaborator OTHER

• Ohio State University

  collaborator OTHER

• St. Joseph's Hospital and Medical Center, Phoenix

  collaborator OTHER

• University of California, San Francisco

  collaborator OTHER

• Oregon Health and Science University

  collaborator OTHER

• Yale New Haven Health System Center for Healthcare Solutions

  collaborator OTHER

• University of Iowa

  collaborator OTHER

• Hartford Hospital

  collaborator OTHER

• The University of Texas Health Science Center, Houston

  collaborator OTHER

• Rhode Island Hospital

  collaborator OTHER

• Stanford University

  collaborator OTHER

• University of Washington

  collaborator OTHER

• University of Calgary

  collaborator OTHER

• Hopital de l'Enfant-Jesus

  collaborator OTHER

• University of Alberta

  collaborator OTHER

• Rush University Medical Center

  collaborator OTHER

• University Hospitals Cleveland Medical Center

  collaborator OTHER

• Columbia University

  collaborator OTHER

• Weill Medical College of Cornell University

  collaborator OTHER

• NYU Langone Health

  collaborator OTHER

• Mount Sinai Hospital, New York

  collaborator OTHER

• Loyola University

  collaborator OTHER

• Beth Israel Deaconess Medical Center

  lead OTHER

Principal Investigators

• Magdy Selim, MD, PhD · Beth Israel Deaconess Medical Center

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

80 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2014-10-31

Primary Completion

2018-02-10

Completion

2018-05-30

Countries

• United States
• Canada

Study Locations